Avid Bioservices Inc (CDMO)

[biopharm]

One of the things she was excited about was building data for what she called an Immuno Score. She was using data from the diagnostic biopsies that all the patients had that led to the diagnosis of their cancer. That would allow them to pick better responding patients (better subsets) for future trials as they would use that similar to way they use ECOG and other scores. I googled immune score and this result led me to believe that she may be contributing to the overall global development on that metric:

The Immunoscore® - as a new possible approach for cancer classification.

Over the past few years, the area of immune regulation at the level of the tumor microenvironment has gained a forefront position in cancer research. At the same time, advances have been made in the development of an immune score, called "Immunoscore"®, as a prognostic factor.

In an effort to promote the Immunoscore in routine clinical settings, a worldwide task force was initiated by Dr Galon.

The working group composed of international expert pathologists and immunologists identified a strategy for the organization of a worldwide participation by various groups for the validation of the Immunoscore

An immune-classification of tumors was proposed based on an immune score, performed by the quantification of two lymphocyte populations (CD3/CD8, or CD3/CD45RO, or CD8/CD45RO), both in the core of the tumor and the invasive margin of the tumor, to establish prognosis of clinical outcome in patients [11]. Importantly, this immune-classification has a prognostic value that may be superior to the AJCC/UICC TNM-classification.


This all should be interesting to biopharm, especially.

Yes EB, I still am excited in my old age when MDSC normally increase, PS flips more, organs like liver can't handle the stress as it used to and repair itself and just about everything decreases with age. Will Biomarkers via Immunoscore help? yes

Will Immunoscore help build a class of surrogate endpoints for cancer? YES

Jerome Galon speaks today and maybe for others, they will begin to understand why I stick with PS Targeting valuations starting at $21 Billion and it just may be advanced quickly....via Immunoscore.

Monday, 6 Nov 2017
09:45-10:25
Hall 1A Plenary lecture: Immunoscore and classification of cancers – Jerome Galon, INSERM, France
Session type: Plenary

http://conference.ncri.org.uk/2017-programme/